KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Idexx Laboratories (IDXX) Cost of Revenue: 2009-2025

Historic Cost of Revenue for Idexx Laboratories (IDXX) over the last 17 years, with Sep 2025 value amounting to $421.9 million.

  • Idexx Laboratories' Cost of Revenue rose 11.17% to $421.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 5.62%. This contributed to the annual value of $1.5 billion for FY2024, which is 3.24% up from last year.
  • Latest data reveals that Idexx Laboratories reported Cost of Revenue of $421.9 million as of Q3 2025, which was up 1.73% from $414.7 million recorded in Q2 2025.
  • In the past 5 years, Idexx Laboratories' Cost of Revenue registered a high of $421.9 million during Q3 2025, and its lowest value of $306.9 million during Q1 2021.
  • For the 3-year period, Idexx Laboratories' Cost of Revenue averaged around $381.9 million, with its median value being $375.4 million (2023).
  • Per our database at Business Quant, Idexx Laboratories' Cost of Revenue skyrocketed by 30.43% in 2021 and then declined by 0.73% in 2022.
  • Over the past 5 years, Idexx Laboratories' Cost of Revenue (Quarterly) stood at $344.7 million in 2021, then fell by 0.30% to $343.6 million in 2022, then increased by 9.25% to $375.4 million in 2023, then rose by 2.18% to $383.6 million in 2024, then climbed by 11.17% to $421.9 million in 2025.
  • Its Cost of Revenue was $421.9 million in Q3 2025, compared to $414.7 million in Q2 2025 and $375.0 million in Q1 2025.